$-0.17 EPS Expected for Sorrento Therapeutics, Inc. (SRNE)

May 16, 2018 - By Karl Shevlin

Sorrento Therapeutics, Inc. (NASDAQ:SRNE) LogoInvestors sentiment increased to 1.53 in Q4 2017. Its up 0.86, from 0.67 in 2017Q3. It improved, as 7 investors sold Sorrento Therapeutics, Inc. shares while 8 reduced holdings. 11 funds opened positions while 12 raised stakes. 8.46 million shares or 1.81% more from 8.31 million shares in 2017Q3 were reported.
California Employees Retirement Sys stated it has 0% in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). The Massachusetts-based Acadian Asset Mgmt Ltd Com has invested 0% in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). Moreover, Bankshares Of America Corporation De has 0% invested in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). Wildcat Limited Liability has invested 7.03% in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). Maryland-based Price T Rowe Assoc Md has invested 0% in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). 72,000 are owned by Matrix Asset Advisors Inc New York. 1,307 were reported by Meeder Asset Mngmt. The Kansas-based Creative Planning has invested 0% in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). Morgan Stanley has invested 0% of its portfolio in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). Jpmorgan Chase & owns 68,179 shares for 0% of their portfolio. Dimensional Fund Advsrs Lp accumulated 36,894 shares. Blackrock holds 0% in Sorrento Therapeutics, Inc. (NASDAQ:SRNE) or 968,284 shares. Northern has invested 0% in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). Royal Bankshares Of Canada accumulated 0% or 147 shares. 460,620 are held by Geode Capital Mgmt Lc.

Since January 23, 2018, it had 2 buys, and 4 insider sales for $11.11 million activity. Ji Henry bought $642,770 worth of stock. Asia Pacific MedTech (BVI) Ltd also sold $5.18M worth of Sorrento Therapeutics, Inc. (NASDAQ:SRNE) shares. 90,000 shares valued at $895,500 were bought by Ng George K on Wednesday, February 28.

Analysts expect Sorrento Therapeutics, Inc. (NASDAQ:SRNE) to report $-0.17 EPS on May, 21.They anticipate $0.28 EPS change or 62.22 % from last quarter’s $-0.45 EPS. The stock increased 4.45% or $0.325 during the last trading session, reaching $7.625. About 343,242 shares traded. Sorrento Therapeutics, Inc. (NASDAQ:SRNE) has risen 53.66% since May 16, 2017 and is uptrending. It has outperformed by 42.11% the S&P500.

Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Ratings Coverage

Among 2 analysts covering Sorrento Therapeutics (NASDAQ:SRNE), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Sorrento Therapeutics has $40 highest and $9.0 lowest target. $25’s average target is 227.87% above currents $7.625 stock price. Sorrento Therapeutics had 11 analyst reports since January 19, 2018 according to SRatingsIntel. The rating was maintained by H.C. Wainwright with “Buy” on Monday, May 14. On Tuesday, January 23 the stock rating was maintained by H.C. Wainwright with “Buy”. H.C. Wainwright maintained Sorrento Therapeutics, Inc. (NASDAQ:SRNE) rating on Tuesday, April 3. H.C. Wainwright has “Buy” rating and $40 target. H.C. Wainwright maintained Sorrento Therapeutics, Inc. (NASDAQ:SRNE) rating on Tuesday, March 6. H.C. Wainwright has “Buy” rating and $38.0 target. The rating was maintained by H.C. Wainwright on Friday, May 4 with “Buy”. The firm has “Buy” rating by Oppenheimer given on Friday, April 6. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, February 20. Oppenheimer maintained Sorrento Therapeutics, Inc. (NASDAQ:SRNE) on Friday, January 19 with “Buy” rating. On Thursday, March 1 the stock rating was maintained by Oppenheimer with “Buy”. As per Thursday, February 1, the company rating was maintained by H.C. Wainwright.

Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. The company has market cap of $707.79 million. It develops therapeutic products for the treatment of auto-immune, inflammatory, neurodegenerative, and infectious diseases. It has a 58.65 P/E ratio. The firm offers resiniferatoxin, a non-opioid TRPV1 agonist neurotoxin for the treatment of intractable pain at end-stage disease.

Another recent and important Sorrento Therapeutics, Inc. (NASDAQ:SRNE) news was published by Globenewswire.com which published an article titled: “Consolidated Research: 2018 Summary Expectations for Sunstone Hotel Investors, Plains All American Pipeline …” on May 11, 2018.

Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: